DXCM
DEXCOM INC
Nasdaq: DXCM · San Diego, CA · Healthcare
$77.94-0.38 (-0.49%)Closed
Market Cap$29.41B
Cash$1.10Bmost recent
Runwayprofitable
P/E (TTM)37.3EPS $2.09
52-Wk Range$54.84 – $92.34
Avg Volume5.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$77.94+4.1%
Pipeline
Drug candidates sponsored by DEXCOM · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Unnamed | Type 2 Diabetes on Insulin | Active, not recruiting | 2026-11-02 | 1 | |
| Phase 1 | Basal insulin | Type 2 Diabetes | Active, not recruiting | 2026-01-16past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 1+1 more | Completed | 2008-06past | 1 | |
| N/A | Unnamed | Type 1 Diabetes Mellitus | Completed | 2008-08past | 1 | |
| N/A | Unnamed | Diabetes+1 more | Completed | 2009-07past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2010-04past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2010-10past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2011-12past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2012-02past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2012-10past | 1 | |
| N/A | Unnamed | Pediatric Subjects With Diabetes Mellitus | Completed | 2012-12past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2012-12past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2013-01past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2014-03past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2016-04past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2016-11past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2017-03-04past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2017-07past | 1 | |
| N/A | Unnamed | Diabetes | Unknown | 2019-05-31past | 1 | |
| N/A | Unnamed | Diabetes+2 more | Completed | 2019-07-22past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2 | Completed | 2020-05-27past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Unknown | 2020-12past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2 | Completed | 2021-01-04past | 1 | |
| N/A | Unnamed | Diabetes | Completed | 2021-03-16past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2021-08-09past | 1 | |
| N/A | Unnamed | Patients Needing Glucose Control | Unknown | 2021-12past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Completed | 2022-02-07past | 1 | |
| N/A | Unnamed | Diabetes Mellitus, Type 2+1 more | Unknown | 2022-02-27past | 1 | |
| N/A | Unnamed | Diabetes Mellitus | Unknown | 2022-03-31past | 1 | |
| N/A | Unnamed | Dysglycemia | Completed | 2023-11-29past | 1 | |
| N/A | Unnamed | Diabetes | Unknown | 2023-12-30past | 1 | |
| N/A | Unnamed | Type 2 Diabetes | Active, not recruiting | 2026-05-13past | 1 | |
| N/A | Unnamed | Diabetes | Active, not recruiting | 2028-03-31 | 1 | |
| N/A | Unnamed | Diabetes | Not yet recruiting | 2030-05-01 | 1 | |
| N/A | Unnamed | Type 1 Diabetes Mellitus | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for DXCM. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.